Mark Goldsmith is the founder of Revolution Medicines. Revolution Medicines has raised $2.1B in total funding. Latest round: IPO.
Mark A. Goldsmith, M.D., Ph.D., is the Chairman, CEO, and President of Revolution Medicines, a biopharmaceutical company focused on developing therapies for RAS-addicted cancers. He co-founded the company in February 2015 alongside Third Rock Ventures. Under his leadership, Revolution Medicines has raised $2.1 billion through public stock offerings and convertible notes.
Full founder directory · Investor directory · Company funding database · Fundraising library